Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | OGG1 | O15527 | 1/20 | 0.52 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694356 | 0.87 | KDM4E (0.50) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1305020 | 0.82 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL241664 | 0.82 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL25894500 | 0.81 | ALDH1A1 (0.65) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL15348715 | 0.81 | GSK3B (0.55) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL9909658 | 0.80 | GSK3B (0.67) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL70930 | 0.80 | GSK3B (1.00) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL3469826 | 0.80 | GSK3B (0.71) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL301099 | 0.78 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL301100 | 0.78 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178385-B | Coumarin hemicyanine dye with structural rigidity, and preparation method and application thereof | 山西大学 | 2025-01-28 | — | — | CN | claimed |
| CN-114835698-B | (diphenylamino) phenyl flavonoid fluorescent probe for detecting cysteine and preparation method thereof | 南京林业大学 | 2024-03-15 | — | — | CN | claimed |
| CN-114751870-B | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof | 贵州医科大学 | 2023-10-20 | — | — | CN | claimed |
| CN-116515782-A | Amine dehydrogenase mutant and application thereof in chiral amine alcohol compound synthesis | 中国科学院天津工业生物技术研究所 | 2023-08-01 | — | — | CN | claimed |
| CN-116178385-A | Coumarin hemicyanine dye with structural rigidity, and preparation method and application thereof | 山西大学 | 2023-05-30 | — | — | CN | claimed |
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | claimed |
| CN-114835698-A | (diphenylamino) phenyl flavonoid fluorescent probe for detecting cysteine and preparation method thereof | 南京林业大学 | 2022-08-02 | — | — | CN | claimed |
| CN-114751870-A | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof | 贵州医科大学 | 2022-07-15 | — | — | CN | claimed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | claimed |
| CN-111233801-B | Colorimetric probe for rapidly detecting solvent components and preparation method and application thereof | 北京师范大学 | 2021-09-07 | — | — | CN | claimed |
| CN-111548280-B | Fluorescent probe for rapidly identifying mercury and methyl mercury as well as preparation method and application thereof | 北京师范大学 | 2021-04-20 | — | — | CN | claimed |
| CN-108484511-A | A kind of ligustrazine chalcone compounds and its preparation method and application | 山东大学 | 2018-09-04 | — | — | CN | claimed |
| CN-106008475-A | Coumarin NEDD8 activating enzyme inhibitor | 南京工业大学 | 2016-10-12 | — | — | CN | claimed |
| CN-104560745-A | Pichia sp.SIT2014 and culture method and application thereof | SHANGHAI INST TECHNOLOGY | 2015-04-29 | — | — | CN | claimed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | claimed |
| EP-2393771-A1 | Method for the synthesis of chiral alpha-aryl propionic acid derivatives | DSM IP Assets B.V. (NL) | 2011-12-14 | — | — | EP | claimed |
| WO-2010089343-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-08-12 | — | — | WO | claimed |
| CN-101580445-A | Method for microwave synthesis of alpha-hydroxyacetophenone series compounds | UNIV JIANGNAN (CN) | 2009-11-18 | — | — | CN | claimed |
| US-4067866-A | Process for preparing cephalosporins and certain novel 2β-thiohydrazo-azetidinones as intermediates | SOCIETA' FARMACEUTICI ITALIA (IT) | 1978-01-10 | — | — | US | claimed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025103442-A1 | SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119371410-A | Chromone spiro compound and preparation method and application thereof | 中国药科大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-116178385-B | Coumarin hemicyanine dye with structural rigidity, and preparation method and application thereof | 山西大学 | 2025-01-28 | — | — | CN | disclosed |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-12-24 | — | — | US | disclosed |
| CN-118812521-A | Benzo heterocyclic compound and application thereof | 中科中山药物创新研究院 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024179529-A1 | SUBSTITUTED TRICYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| CN-118140931-A | Application of chromene-thiazole/oxazolamine compound | 贵州医科大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-114805224-B | Ligustrazine chalcone derivative and preparation method and application thereof | 山东大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-115806493-B | Method for synthesizing epstein chiral intermediate by asymmetric hydrogenation | 南京工业大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-114835698-B | (diphenylamino) phenyl flavonoid fluorescent probe for detecting cysteine and preparation method thereof | 南京林业大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-114835698-B | (diphenylamino) phenyl flavonoid fluorescent probe for detecting cysteine and preparation method thereof | 南京林业大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-117683026-A | 3-tetrahydrofuran chromone compound and diastereoisomeric divergent preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2024-03-12 | — | — | CN | disclosed |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-114105753-B | Fisetin derivative and application thereof in preparation of anti-inflammatory drugs | 温州医科大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-117164845-B | Preparation method and application of polymethine nanocluster | 吉林大学第一医院 | 2024-02-09 | — | — | CN | disclosed |
| CN-113999223-B | Thiazole-containing flavonoid derivative, preparation method and application thereof | 扬州大学 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023234187-A1 | METHOD FOR PRODUCING ORGANIC COPPER COMPOUND | シンクレスト株式会社 | 2023-12-07 | — | — | WO | disclosed |
| CN-117164845-A | Preparation method and application of polymethine nanocluster | 吉林大学第一医院 | 2023-12-05 | — | — | CN | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| CN-114751870-B | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof | 贵州医科大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-116515782-A | Amine dehydrogenase mutant and application thereof in chiral amine alcohol compound synthesis | 中国科学院天津工业生物技术研究所 | 2023-08-01 | — | — | CN | disclosed |
| US-11701373-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-18 | — | — | US | disclosed |
| CN-114057626-B | Indole-2, 3-dione derivative, preparation method thereof and anti-liver cancer drug for inhibiting RECQL4 specific expression | 山东第一医科大学(山东省医学科学院) | 2023-06-30 | — | — | CN | disclosed |
| WO-2023120645-A1 | ORGANIC ZINC COMPOUND AND PRODUCTION METHOD FOR ORGANIC ZINC COMPOUND | シンクレスト株式会社 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023120647-A1 | ORGANIC COPPER COMPOUND, AND METHOD FOR PRODUCING ORGANIC COPPER COMPOUND | シンクレスト株式会社 | 2023-06-29 | — | — | WO | disclosed |
| CN-116178385-A | Coumarin hemicyanine dye with structural rigidity, and preparation method and application thereof | 山西大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-110950860-B | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3473639-B1 | HEPATITIS C VIRUS INHIBITOR AND APPLICATION | ZHEJIANG PALO ALTO PHARMACEUTICALS INC (CN) | 2023-03-29 | — | — | EP | disclosed |
| CN-115806493-A | Method for synthesizing chiral ebavir intermediate by asymmetric hydrogenation | 南京工业大学 | 2023-03-17 | — | — | CN | disclosed |
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | disclosed |
| US-20220387615-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-12-08 | — | — | US | disclosed |
| US-20220387615-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-12-08 | — | — | US | disclosed |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| CN-110386927-B | Histone Acetyltransferase (HAT) inhibitors and uses thereof | 中国科学院上海药物研究所 | 2022-09-23 | — | — | CN | disclosed |
| CN-115040497-A | Application of paeonol derivative in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-09-13 | — | — | CN | disclosed |
| CN-110773223-B | g-C 3 N 4 Supported transition metal oxide and application thereof in synthesis of alpha-hydroxy ketone | 南京理工大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-115010688-A | One-pot preparation method of 4-chromanone, congeners and derivatives thereof | 烟台六谛医药科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-4038066-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114835698-A | (diphenylamino) phenyl flavonoid fluorescent probe for detecting cysteine and preparation method thereof | 南京林业大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-113135814-B | Method for synthesizing chiral 1, 2-diol compound | 温州大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-114835698-A | (diphenylamino) phenyl flavonoid fluorescent probe for detecting cysteine and preparation method thereof | 南京林业大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-114805224-A | Ligustrazine chalcone derivative and preparation method and application thereof | 山东大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-114787159-A | BRM targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114751870-A | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof | 贵州医科大学 | 2022-07-15 | — | — | CN | disclosed |
| EP-3990027-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | Danmarks Tekniske Universitet (DK) | 2022-05-04 | — | — | EP | disclosed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | disclosed |
| CN-114105753-A | Fisetin derivative and application thereof in preparation of anti-inflammatory drugs | 温州医科大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114057626-A | Indole-2, 3-dione derivative, preparation method thereof and anti-liver cancer drug for inhibiting RECQL4 specific expression | 山东第一医科大学(山东省医学科学院) | 2022-02-18 | — | — | CN | disclosed |
| CN-113999223-A | Flavone derivative containing thiazole, preparation method and application thereof | 扬州大学 | 2022-02-01 | — | — | CN | disclosed |
| CN-110511233-B | Thiazolo [2,3-b ] oxazolone compound and preparation method and application thereof | 成都大学 | 2022-01-25 | — | — | CN | disclosed |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SUZHOU INSTITUTE OF MATERIA MEDICA (CN) | 2022-01-06 | — | — | US | disclosed |
| WO-2021238588-A1 | OXATHIAZINE COMPOUND AND USE THEREOF | 四川大学华西医院 | 2021-12-02 | — | — | WO | disclosed |
| CN-108558813-B | Resveratrol derivative containing flavonoid as well as preparation method and application thereof | 合肥工业大学 | 2021-07-23 | — | — | CN | disclosed |
| CN-113135814-A | Method for synthesizing chiral 1, 2-diol compound | 温州大学 | 2021-07-20 | — | — | CN | disclosed |
| US-11058696-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| CN-110066278-B | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3183242-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-109134481-B | Substituted pyrrole chromone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中山大学 | 2021-05-14 | — | — | CN | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-08 | — | — | US | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| CN-111518058-B | Oxathiazine compound and application thereof | 四川大学华西医院 | 2021-03-09 | — | — | CN | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-107522716-B | Hepatitis C virus inhibitor and application thereof | 浙江柏拉阿图医药科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112166114-A | BRM targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-01 | — | — | CN | disclosed |
| WO-2020260597-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | DANMARKS TEKNISKE UNIVERSITET (DK) | 2020-12-30 | — | — | WO | disclosed |
| CN-108906053-B | Hydrophobic hydrotalcite loaded bimetallic catalyst and oxidation catalysis application thereof | 中国科学院兰州化学物理研究所苏州研究院 | 2020-11-03 | — | — | CN | disclosed |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| EP-2972399-B1 | LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2020-09-02 | — | — | EP | disclosed |
| CN-111518058-A | Oxathiazine compound and application thereof | 四川大学华西医院 | 2020-08-11 | — | — | CN | disclosed |
| US-10709719-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| CN-107148409-B | Substituted bicyclic compounds | 百时美施贵宝公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-3658548-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10640515-B2 | Hepatitis C virus inhibitor and uses thereof | ZHEJIANG PALO ALTO PHARMACEUTICALS, INC (CN) | 2020-05-05 | — | — | US | disclosed |
| EP-3256468-B1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| CN-110950860-A | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2020-02-20 | — | — | US | disclosed |
| CN-110773223-A | g-C 3N 4Supported transition metal oxide and application thereof in synthesis of α -hydroxyketone | 南京理工大学 | 2020-02-11 | — | — | CN | disclosed |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
| CN-105884758-B | Tricyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2019-12-10 | — | — | CN | disclosed |
| WO-2019195201-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2019-10-03 | — | — | US | disclosed |
| CN-110015983-A | 1,2- dicarbapentaborane class compound and its synthetic method | 华东师范大学 | 2019-07-16 | — | — | CN | disclosed |
| US-20190135828-A1 | HEPATITIS C VIRUS INHIBITOR AND USES THEREOF | ZHEJIANG PALO ALTO PHARMACEUTICALS,INC (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3473639-A1 | HEPATITIS C VIRUS INHIBITOR AND APPLICATION | Zhejiang Palo Alto Pharmaceuticals, Inc (CN) | 2019-04-24 | — | — | EP | disclosed |
| US-20190076450-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2019023553-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| CN-109134481-A | A kind of substituted azole chromogen ketone compounds or its pharmaceutically acceptable salt and its preparation method and application | 中山大学 | 2019-01-04 | — | — | CN | disclosed |
| US-10166249-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| CN-108906053-A | Hydrophobic water talcum supported bimetal catalyst and its oxidation catalysis application | 中国科学院兰州化学物理研究所苏州研究院 | 2018-11-30 | — | — | CN | disclosed |
| CN-108484511-A | A kind of ligustrazine chalcone compounds and its preparation method and application | 山东大学 | 2018-09-04 | — | — | CN | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-3256468-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-12-20 | — | — | EP | disclosed |
| CN-104560745-B | A kind of Pichia yeast Pichia sp.SIT2014 and its cultural method and application | 上海应用技术学院 | 2017-12-01 | — | — | CN | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170304332-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-9770459-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170042917-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170038642-A1 | ALIGNMENT LAYER AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-09 | — | — | US | disclosed |
| EP-2939683-B1 | Apolipoprotein A-I Mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-9522888-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| CN-106008475-A | Coumarin NEDD8 activating enzyme inhibitor | 南京工业大学 | 2016-10-12 | — | — | CN | disclosed |
| WO-2016127924-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-18 | — | — | WO | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| US-20160185763-A1 | LIQUID CRYSTAL STABILIZER, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160052888-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-25 | — | — | US | disclosed |
| WO-2014082379-A9 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-02-25 | — | — | WO | disclosed |
| CN-105051036-A | Flavonoid or isoflavone compound and application thereof | SHANGHAI ZHENGJI PHARMACEUTICALS CO LTD | 2015-11-11 | — | — | CN | disclosed |
| EP-2939683-A1 | Apolipoprotein A-I Mimics | Cerenis Therapeutics Holding SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| WO-2015162538-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS FOR THE TREATMENT OF HYPERPARATHYROIDISM, CHRONIC RENAL FAILURE AND CHRONIC KIDNEY DISEASE | LUPIN LIMITED (IN) | 2015-10-29 | — | — | WO | disclosed |
| CN-103059042-B | Thiophene derivants and the purposes in pharmacy thereof | GINKGO PHARMACEUTICAL (SUZHOU) CO., LTD. (CN) | 2015-10-07 | — | — | CN | disclosed |
| CN-104817483-A | Bis carbonyl indole compound and synthesis method | UNIV EAST CHINA NORMAL | 2015-08-05 | — | — | CN | disclosed |
| EP-2396017-B1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-07-01 | — | — | EP | disclosed |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-05-21 | — | — | US | disclosed |
| CN-103408414-B | Preparation method of 2-hydroxyl-4-substituted arone compound | BEIJING GREENCHEM TECHNOLOGY CO LTD | 2015-05-13 | — | — | CN | disclosed |
| CN-104560745-A | Pichia sp.SIT2014 and culture method and application thereof | SHANGHAI INST TECHNOLOGY | 2015-04-29 | — | — | CN | disclosed |
| US-8993597-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-03-31 | — | — | US | disclosed |
| CN-104177241-A | Alkynyl diketone compound and synthetic method thereof | UNIV EAST CHINA NORMAL | 2014-12-03 | — | — | CN | disclosed |
| CN-103408414-A | Preparation method of 2-hydroxyl-4-substituted arone compound | BEIJING GREENCHEM TECHNOLOGY CO LTD | 2013-11-27 | — | — | CN | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| CN-103304571-A | Spiro compound as well as preparation method, intermediate, pharmaceutical composition and application thereof | SHANGHAI YUNYI HEALTH ADMINISTRATION CONSULTING CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-09-05 | — | — | US | disclosed |
| CN-103059042-A | Thiophene derivative and application thereof to medicine | GINKGO PHARMA CO LTD | 2013-04-24 | — | — | CN | disclosed |
| US-8378068-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2504339-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| CN-102712648-A | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG | 2012-10-03 | — | — | CN | disclosed |
| US-8263797-B2 | Method for producing cyclopropane carboxylic acid compound and intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-102617585-A | Furocoumarin derivative, preparation method thereof and use thereof | SHANGHAI INST MATERIA MEDICA | 2012-08-01 | — | — | CN | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| EP-2393771-A1 | Method for the synthesis of chiral alpha-aryl propionic acid derivatives | DSM IP Assets B.V. (NL) | 2011-12-14 | — | — | EP | disclosed |
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-16 | — | — | US | disclosed |
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-16 | — | — | US | disclosed |
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| WO-2011064211-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20100280267-A1 | METHOD FOR PRODUCING CYCLOPROPANE CARBOXYLIC ACID COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-1951725-B1 | N-SULFAMOYL-N -BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | ABBOTT PRODUCTS GMBH (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2010-10-21 | — | — | US | disclosed |
| EP-2241551-A1 | METHOD FOR PRODUCING CYCLOPROPANE CARBOXYLIC ACID COMPOUND AND INTERMEDIATE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010117635-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| CN-101006087-B | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER | 2010-09-29 | — | — | CN | disclosed |
| WO-2010089343-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010054279-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| CN-101580445-A | Method for microwave synthesis of alpha-hydroxyacetophenone series compounds | UNIV JIANGNAN (CN) | 2009-11-18 | — | — | CN | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| CN-101534811-A | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | ORGANON NV (NL) | 2009-09-16 | — | — | CN | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7547708-B2 | N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALS, INC. (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| EP-1951725-A1 | N-SULFAMOYL-N -BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | Solvay Pharmaceuticals GmbH (DE) | 2008-08-06 | — | — | EP | disclosed |
| CN-101094848-A | Organic compounds | NOVARTIS AG (CH) | 2007-12-26 | — | — | CN | disclosed |
| EP-1833816-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| CN-101006087-A | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALSS GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| WO-2007054580-A1 | N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1778686-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006018718-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050256124-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005103039-A1 | 2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| CN-1688549-A | Compound having TGF-beta inhibitory activity and medicinal composition containing the same | KIRIN BREWERY (JP) | 2005-10-26 | — | — | CN | disclosed |
| CN-1182129-C | Benzopyran derivatives having leukotriene-antagonistic action | ������ʵ���ҹ�˾ | 2004-12-29 | — | — | CN | disclosed |
| CN-1149196-C | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | ����˹�ж�-����˹˹������˾ | 2004-05-12 | — | — | CN | disclosed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| US-6703181-B1 | COMPRISING AT LEAST ONE OF: IMIDAZOLE COMPOUND, AN ALANINE COMPOUND, AN ADENINE COMPOUND, AN ADENOSINE COMPOUND, AND A QUATERNARY AMMONIUM SALT COMPOUND, AND WHICH INCREASES MISCIBILITY IN A RESIST FILM | KABUSHIKI KAISHA TOSHIBA (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20020082264-A1 | Medicaments for viral diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-27 | — | — | US | disclosed |
| WO-2002020509-A2 | MEDICAMENTS AGAINST VIRAL INFECTIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| US-6110910-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANTIRHEUMATIC AGENTS, ANTICARCINOGENIC AGENTS | DUPONT PHARMACEUTICALS (US) | 2000-08-29 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| CN-1214048-A | Benzopyran derivatives having leukotriene-antagonistic action | LABROATORIOS MENARINI S A (ES) | 1999-04-14 | — | — | CN | disclosed |
| US-5874441-A | TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
| US-5744281-A | P-HYDROXYSTYRENE POLYMER | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0624163-B1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMA (IT) | 1998-03-25 | — | — | EP | disclosed |
| US-5658706-A | CONTAINING COMPOUND WHICH DECOMPOSES INTO AN ACID | KABUSHIKI KAISHA TOSHIBA (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5639759-A | ORGAN TRANSPLANTATION; AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTIARTHRITIC AGENTS; ANTICANCER AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0716652-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5428040-A | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1995006640-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1995004046-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| EP-0624163-A1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993015106-A1 | CYCLIC CALCITONINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1993-08-05 | — | — | WO | disclosed |
| EP-0181121-B1 | NOVEL POLYPEPTIDE AND PROCESS FOR PRODUCING THE SAME | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
| EP-0137534-B1 | ONE-POT PROCESS FOR PREPARATION OF 7BETA-AMINO- AND 7BETA-ACYLAMINO- 3-SUBSTITUTED METHYL-3-CEPHEM-4-CARBOXYLIC ACID DERIVATIVES AND PROCESS FOR DEOXYGENATION OF 7BETA-ACYLAMINO-3-CEPHEM-4-CARBOXYLIC ACID 1-OXIDE DERIVATIVES | GIST-BROCADES N.V. (NL) | 1990-05-16 | — | — | EP | disclosed |
| US-RE33188-E | Peptides for assaying human parathyroid hormone | TOYO JOZO KABUSHIKI KAISHA (JP) | 1990-03-27 | — | — | US | disclosed |
| EP-0119705-B1 | OCTAPEPTIDE VASOPRESSIN ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4719199-A | VASORPRESSIN ANTAGONIST | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4703106-A | REDUCING CALCIUM CONCENTRATION OF BLOOD | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1987-10-27 | — | — | US | disclosed |
| US-4695627-A | PHOSPHORUS PENTACHLORIDE, OLEFIN | GIST-BROCADES N.V. (NL) | 1987-09-22 | — | — | US | disclosed |
| US-4684716-A | VASOPRESSIN ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-04 | — | — | US | disclosed |
| US-4656250-A | NORLEUCINE, TYROSINE, PHENYLALANINE TREATING HYPOPARATHYROIDISM | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-04-07 | — | — | US | disclosed |
| US-4597901-A | POLYPEPTIDES, DIURESIS | SMITHKLINE BECKMAN CORPORATION (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0181121-A2 | Novel polypeptide and process for producing the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| US-4587045-A | Intermediates for preparing octapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-06 | — | — | US | disclosed |
| US-4542124-A | Octapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-09-17 | — | — | US | disclosed |
| EP-0137534-A2 | One-pot process for preparation of 7beta-amino- and 7beta-acylamino- 3-substituted methyl-3-cephem-4-carboxylic acid derivatives and process for deoxygenation of 7beta-acylamino-3-cephem-4-carboxylic acid 1-oxide derivatives | GIST-BROCADES N.V. (NL) | 1985-04-17 | — | — | EP | disclosed |
| EP-0119705-A2 | Octapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-09-26 | — | — | EP | disclosed |
| US-4409141-A | Peptides for assaying human parathyroid hormone | TOYO JOZO KABUSHIKI KAISHA (JP) | 1983-10-11 | — | — | US | disclosed |
| US-4400316-A | POLYPEPTIDES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1983-08-23 | — | — | US | disclosed |
| US-4258193-A | FOR IMMOBILIZATION; IMMUNOASSAY, CROSSLINKING OF PROTEINS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | disclosed |
| US-4234578-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4086221-A | SERUM CALCIUM REDUCING ACTIVITY | TOYO JOZO KABUSHIKI KAISHA (JA) | 1978-04-25 | — | — | US | disclosed |
| US-4075227-A | NONSTEROIDAL | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075223-A | NONSTEROIDAL | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4017546-A | AROYL PHENYL INDENES AND AROYL PHENYL NAPHTHALENES | ELI LILLY AND COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-3962224-A | CHEMICAL INTERMEDIATES FOR ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3962224-A | CHEMICAL INTERMEDIATES FOR ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (48 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | GSK3B 449/4885HDAC1 677/4885HDAC8 860/4885 |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | GSK3B 707/4885HDAC1 714/4885HDAC8 806/4885 |
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | CYP1B1, CYP11B2, CCNI | GSK3B 1516/4885HDAC1 579/4885HDAC8 1356/4885 |
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | GSK3B 1229/4885HDAC1 500/4885HDAC8 629/4885 |
| US-20020082264-A1 | Medicaments for viral diseases | IRF3, STING1, EIF2AK2 | GSK3B 672/4885HDAC1 1380/4885HDAC8 726/4885 |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | GSK3B 1404/4885HDAC1 411/4885HDAC8 683/4885 |
| US-20190135828-A1 | HEPATITIS C VIRUS INHIBITOR AND USES THEREOF | HAVCR2, ZC3HAV1, HCCS | GSK3B 2012/4885HDAC1 1311/4885HDAC8 1620/4885 |
| US-20170042917-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | GSK3B 2139/4885HDAC1 908/4885HDAC8 827/4885 |
| US-20160052888-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | GSK3B 3441/4885HDAC1 3318/4885HDAC8 3979/4885 |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | EP300, HDAC11, HDAC1 | GSK3B 612/4885HDAC1 3/4885HDAC8 7/4885 |
| US-10166249-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | GSK3B 1760/4885HDAC1 422/4885HDAC8 418/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | GSK3B 1229/4885HDAC1 500/4885HDAC8 629/4885 |
| US-20100280267-A1 | METHOD FOR PRODUCING CYCLOPROPANE CARBOXYLIC ACID COMPOUND AND INTERMEDIATE THEREFOR | FAR1, CYP51A1, CYP4A11 | GSK3B 3793/4885HDAC1 901/4885HDAC8 793/4885 |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SCN2A, NAPEPLD, SCN5A | GSK3B 2422/4885HDAC1 626/4885HDAC8 2030/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | GSK3B 4475/4885HDAC1 994/4885HDAC8 3023/4885 |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | GSK3B 1229/4885HDAC1 500/4885HDAC8 629/4885 |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | GSK3B 2139/4885HDAC1 908/4885HDAC8 827/4885 |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | GSK3B 3441/4885HDAC1 3318/4885HDAC8 3979/4885 |
| US-11701373-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | NR1H4, SLC10A1, SLC10A2 | GSK3B 176/4885HDAC1 807/4885HDAC8 483/4885 |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | GSK3B 509/4885HDAC1 1277/4885HDAC8 3285/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | GSK3B 4596/4885HDAC1 980/4885HDAC8 2675/4885 |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | GSK3B 403/4885HDAC1 475/4885HDAC8 799/4885 |
| US-11058696-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-10640515-B2 | Hepatitis C virus inhibitor and uses thereof | CLIC1, HAVCR2, ZC3HAV1 | GSK3B 3564/4885HDAC1 665/4885HDAC8 2314/4885 |
| US-20190300521-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | GSK3B 2139/4885HDAC1 908/4885HDAC8 827/4885 |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | GSK3B 3441/4885HDAC1 3318/4885HDAC8 3979/4885 |
| US-20160185763-A1 | LIQUID CRYSTAL STABILIZER, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME, AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | PYM1, YBX3, MLX | GSK3B 1542/4885HDAC1 2958/4885HDAC8 4178/4885 |
| US-20220387615-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | ADAM17, ADAM8, ADAM33 | GSK3B 3088/4885HDAC1 1404/4885HDAC8 1265/4885 |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | GSK3B 1911/4885HDAC1 573/4885HDAC8 1342/4885 |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | EP300, HDAC11, HDAC1 | GSK3B 612/4885HDAC1 3/4885HDAC8 7/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | GSK3B 2237/4885HDAC1 653/4885HDAC8 677/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | GSK3B 4436/4885HDAC1 1032/4885HDAC8 2680/4885 |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | GSK3B 176/4885HDAC1 807/4885HDAC8 483/4885 |
| US-20170304332-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | GSK3B 3441/4885HDAC1 3318/4885HDAC8 3979/4885 |
| US-10709719-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-11427548-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | GSK3B 1229/4885HDAC1 500/4885HDAC8 629/4885 |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | EP300, HDAC11, HDAC1 | GSK3B 612/4885HDAC1 3/4885HDAC8 7/4885 |
| US-20050256124-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | GSK3B 2163/4885HDAC1 1915/4885HDAC8 2601/4885 |
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | GSK3B 4628/4885HDAC1 1182/4885HDAC8 3118/4885 |
| US-20190076450-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | GSK3B 1819/4885HDAC1 811/4885HDAC8 2146/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | GSK3B 603/4885HDAC1 638/4885HDAC8 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.